Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New care pathway aims to save lives of ICU patients with breathing failure

NCT ID NCT04744298

Disease control Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a step-by-step care plan (called TheraPPP) helps patients with severe breathing failure (ARDS) survive and spend less time on a ventilator. The plan includes proven treatments like protective ventilation, paralysis, and prone positioning. About 20,000 adults in Alberta ICUs will be included. The goal is to make sure every patient gets the best known care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 19,916 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Admitted to the one of the 17 adult Intensive Care Units in Alberta * Invasively mechanically ventilated Exclusion Criteria: * none

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory distress syndrome ARDS, human Hypoxemic respiratory failure

Contacts and locations

Locations

  • Chinook Regional Hospital

    Lethbridge, Alberta, T1J 1W5, Canada

  • Foothills Hospital Intensive Care Unit

    Calgary, Alberta, T2N 2T9, Canada

  • Foothills Medical Center Cardiovascular ICU

    Calgary, Alberta, T2N 2T9, Canada

  • Grey Nuns Community Hospital

    Edmonton, Alberta, T6L 5X8, Canada

  • Mazankowski Alberta Heart Institute

    Edmonton, Alberta, T6G 2B7, Canada

  • Medicine Hat Regional Hospital

    Medicine Hat, Alberta, T1A 4H6, Canada

  • Misericordia Community Hospital

    Edmonton, Alberta, T5R 4H5, Canada

  • Northern Lights Regional Health Centre

    Fort McMurray, Alberta, T9H 1P2, Canada

  • Peter Lougheed Centre (PLC)

    Calgary, Alberta, T1Y 6J4, Canada

  • Queen Elizabeth II Hospital

    Grande Prairie, Alberta, T8V 2E8, Canada

  • Red Deer Regional Hospital Centre

    Red Deer, Alberta, T4N 4E7, Canada

  • Rockyview General Hospital

    Calgary, Alberta, T2V 1P9, Canada

  • Royal Alexandra Hospital

    Edmonton, Alberta, T5H 3V9, Canada

  • South Health Campus

    Calgary, Alberta, T3M 1M4, Canada

  • Sturgeon Community Hospital

    St. Albert, Alberta, T8N 6C4, Canada

  • University of Alberta Hospital General Systems ICU

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Alberta Hospital Neurosciences Intensive Care Unit

    Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.